AR089489A1 - Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas - Google Patents

Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas

Info

Publication number
AR089489A1
AR089489A1 ARP120105010A ARP120105010A AR089489A1 AR 089489 A1 AR089489 A1 AR 089489A1 AR P120105010 A ARP120105010 A AR P120105010A AR P120105010 A ARP120105010 A AR P120105010A AR 089489 A1 AR089489 A1 AR 089489A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
alkoxy
substituted
cycloalkyl
Prior art date
Application number
ARP120105010A
Other languages
English (en)
Inventor
Young Byun Eun
Ah Jun Seung
Gil Ahn Young
Hyun Suh Kwee
Hwan Bae In
Beom Son Jung
Mi Han Sang
Joo Kwak Eun
Seok Kim Ho
Young Song Ji
Original Assignee
27
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48697978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089489(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 27 filed Critical 27
Publication of AR089489A1 publication Critical patent/AR089489A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Tienen actividad inhibidora para la quinasa de las proteínas, y una composición farmacéutica que los comprende para la prevención y el tratamiento de enfermedades del crecimiento celular anormal. Reivindicación 1: Un derivado de tieno[3,2-d]pirimidina de la fórmula (1) o una de sus sales aceptables desde el punto de vista farmacéutico, en donde: A es hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆, heterocicloalquilo de 3 a 6 miembros, arilo C₆₋₁₀ o heteroarilo de 5 a 10 miembros, en donde dicho arilo o heteroarilo está reducido en forma opcional o sustituido con hidrógeno; W es O, S, S(O), S(O)₂, NH, -NHNH- o heterocicloalquilo de 3 a 6 miembros; X e Y son, cada uno en forma independiente CH o N; Z es hidrógeno, alquilo C₁₋₃ o NR³R⁴, en donde dicho R³ y R⁴ son, cada uno en forma independiente hidrógeno, alquilo C₁₋₆ o -(CH₂)q-B-, B representa NR⁵R⁶, alcoxi C₁₋₆, cicloalquilo C₃₋₆ o heterocicloalquilo de 3 a 6 miembros; R¹ es hidrógeno, halógeno, alquilo C₁₋₃ o alcoxi C₁₋₃, en donde dicho alquilo o alcoxi no está sustituido o está sustituido con uno o más átomos de halógeno; R² es hidrógeno, halógeno, -CF₃, -NO₂, -OH, -CN, alcoxi C₁₋₆, alquilo C₁₋₆, alquenilo C₂₋₄, alquinilo C₂₋₄, -NR⁷R⁸, -NHSO₂R⁹, -SO₂R¹⁰, -C(O)R¹¹, -NHC(O)R¹², -NHC(O)OR¹³, -S(O)R¹⁴, cicloalquilo C₃₋₆, heterocicloalquilo de 5 a 10 miembros, arilo C₆₋₁₀, ariloxi C₆₋₁₀, heteroarilo de 5 a 10 miembros o heteroariloxi de 3 a 6 miembros, en donde dicho R² está conectado a A por -(CH₂)ₚ- o sustituido con alquilo C₁₋₄, alquinilo C₂₋₄, alquilcarbonilo C₁₋₄ o uno o más átomos de halógeno; R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³ y R¹⁴ son, cada uno en forma independiente hidrógeno, -NH₂, alquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₆ o heterocicloalquilo de 3 a 6 miembros, dicho alquilo, alcoxi, cicloalquilo o heterocicloalquilo no está sustituido o está sustituido con uno o más átomos de halógeno; q es un número entero que oscila desde 0 hasta 3; p es un número entero que oscila desde 0 hasta 3; m es un número entero que oscila desde 0 hasta 5; n es un número entero que oscila desde 0 hasta 2; y cuando A es hidrógeno, m es 0.
ARP120105010A 2011-12-30 2012-12-27 Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas AR089489A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20110146818 2011-12-30

Publications (1)

Publication Number Publication Date
AR089489A1 true AR089489A1 (es) 2014-08-27

Family

ID=48697978

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120105010A AR089489A1 (es) 2011-12-30 2012-12-27 Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas

Country Status (33)

Country Link
US (2) US9156852B2 (es)
EP (2) EP2797927B1 (es)
JP (1) JP5797345B2 (es)
KR (1) KR101490761B1 (es)
CN (1) CN104039798B (es)
AR (1) AR089489A1 (es)
AU (1) AU2012363558C1 (es)
BR (2) BR112014015720B1 (es)
CA (1) CA2859668C (es)
CL (1) CL2014001729A1 (es)
CO (1) CO7010840A2 (es)
DK (1) DK2797927T3 (es)
ES (1) ES2751608T3 (es)
HK (1) HK1200833A1 (es)
HR (1) HRP20191840T8 (es)
HU (1) HUE045957T2 (es)
IL (2) IL233441B (es)
IN (1) IN2014DN06101A (es)
LT (1) LT2797927T (es)
MX (2) MX363659B (es)
MY (1) MY170988A (es)
PE (1) PE20141404A1 (es)
PH (1) PH12014501504A1 (es)
PL (1) PL2797927T3 (es)
PT (1) PT2797927T (es)
RS (1) RS59420B1 (es)
RU (2) RU2705577C2 (es)
SG (2) SG10201701999QA (es)
SI (1) SI2797927T1 (es)
TW (1) TWI462927B (es)
UA (1) UA109614C2 (es)
WO (1) WO2013100632A1 (es)
ZA (1) ZA201405583B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
SI3207023T1 (sl) 2014-10-14 2020-07-31 Syngenta Participations Ag Postopek za pripravo 1-(3,5-diklorofenil)-2,2,2-trifluoroetanona in njegovih derivatov
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
KR20180070695A (ko) 2015-10-29 2018-06-26 이펙터 테라퓨틱스, 인크. Mnk1 및 mnk2의 이소인돌린, 아자이소인돌린, 디히드로인데논 및 디히드로아자인데논 억제제
US20170121339A1 (en) 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
CN106928252B (zh) * 2015-12-31 2019-09-27 成都先导药物开发股份有限公司 一种抑制rock的化合物及其制备方法与应用
EP3414247B1 (en) * 2016-02-08 2021-04-21 F. Hoffmann-La Roche AG Spiroindolinones as ddr1 inhibitors
EP3443114A1 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
CN106153920B (zh) * 2016-07-25 2018-04-27 四川大学华西医院 一种肺癌筛查试剂盒
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
PT3562821T (pt) * 2016-12-28 2021-03-03 Minoryx Therapeutics S L Compostos de isoquinolina, métodos para a sua preparação e utilizações terapêuticas dos mesmos em condições associadas à alteração da atividade da beta-galactosidade
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
MX2019009653A (es) 2017-02-14 2019-12-19 Effector Therapeutics Inc Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos.
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
RS64654B1 (sr) 2017-07-28 2023-10-31 Yuhan Corp Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom
EP3679159A1 (en) 2017-09-08 2020-07-15 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019107987A1 (en) 2017-11-30 2019-06-06 Hanmi Pharm. Co., Ltd. THIENO[3,2-d]PYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE
CA3084073C (en) * 2017-11-30 2023-04-25 Hanmi Pharm. Co., Ltd. Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
JP2021515767A (ja) 2018-03-07 2021-06-24 バイエル・アクチエンゲゼルシヤフト Ｅｒｋ５阻害剤の同定及び使用
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
AU2019366947A1 (en) 2018-10-24 2021-06-03 Effector Therapeutics, Inc. Crystalline forms of Mnk inhibitors
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN110183464B (zh) * 2019-05-31 2021-08-31 淮阴工学院 一种抗癌化合物艾斯替尼及其合成方法和应用
CA3178927A1 (en) 2020-05-26 2021-12-02 Hanmi Pharm. Co., Ltd. Belvarafenib for use in cancer treatment
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
JP2023547306A (ja) 2020-10-27 2023-11-10 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド アリールアミド化合物、それを含む医薬組成物、その製造方法及びそれらの使用
KR20230156731A (ko) 2021-03-09 2023-11-14 제넨테크, 인크. 뇌암 치료에 이용하기 위한 벨바라페닙
JP2024514112A (ja) 2021-04-06 2024-03-28 ジェネンテック， インコーポレイテッド ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法
JP2024513246A (ja) 2021-04-09 2024-03-22 ジェネンテック， インコーポレイテッド Ｒａｆ阻害剤及びｐｄ－１軸阻害剤を用いた併用治療
TW202311265A (zh) 2021-06-30 2023-03-16 美商建南德克公司 ４—胺基—ｎ—（１—（（３—氯—２—氟苯基）胺基）—６—甲基異喹啉—５—基）噻吩并［３，２—］嘧啶—７—甲醯胺之雙甲磺酸鹽及其中間體之合成
CN114213430B (zh) * 2021-12-28 2022-12-02 深圳湾实验室 4-氨基噻吩[3,2-d]嘧啶-7-羧酸的制备方法、蛋白激酶抑制剂中间体
CN114524826A (zh) * 2022-02-18 2022-05-24 郑州猫眼农业科技有限公司 7-溴-4-氯噻吩并[3,2-d]嘧啶的制备工艺
WO2023166345A2 (en) 2022-03-02 2023-09-07 Novartis Ag Precision therapy for the treatment of cancer
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
RU2556984C2 (ru) * 2004-06-24 2015-07-20 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы транспортеров атф-связывающей кассеты
MY146795A (en) 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
BRPI0710181A2 (pt) * 2006-03-16 2011-08-09 Novartis Ag compostos orgánicos
WO2007115822A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnkl /mnk2 inhibiting activity for pharmaceutical compositions
WO2008044688A1 (fr) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Dérivé de l'urée
EP2282995B1 (en) 2008-05-23 2015-08-26 Novartis AG Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
KR20110100241A (ko) * 2008-12-05 2011-09-09 아르퀼 인코포레이티드 Ｒａｆ 억제제 및 이들의 용도
US8691828B2 (en) * 2009-03-05 2014-04-08 Takeda Pharmaceutical Company Limited Thienopyrimidine as CDC7 kinase inhibitors
DE102009035754A1 (de) 2009-07-24 2011-01-27 Hartmetall-Werkzeugfabrik Paul Horn Gmbh Schneideinsatz für ein Schneidwerkzeug zur spanenden Bearbeitung, insbesondere zum Hochvorschubfräsen
WO2011025940A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
KR101147550B1 (ko) 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
KR101094446B1 (ko) 2009-11-19 2011-12-15 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
JP5676650B2 (ja) * 2010-01-29 2015-02-25 ハンミ・サイエンス・カンパニー・リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． プロテインキナーゼ阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
MX340490B (es) * 2010-07-13 2016-07-11 F Hoffmann-La Roche Ag * Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).

Also Published As

Publication number Publication date
UA109614C2 (uk) 2015-09-10
CN104039798A (zh) 2014-09-10
AU2012363558A1 (en) 2014-08-21
TW201331209A (zh) 2013-08-01
PH12014501504B1 (en) 2014-10-08
SI2797927T1 (sl) 2019-12-31
PL2797927T3 (pl) 2019-12-31
US20140371219A1 (en) 2014-12-18
LT2797927T (lt) 2019-10-25
IN2014DN06101A (es) 2015-08-14
IL266285A (en) 2019-06-30
CL2014001729A1 (es) 2014-09-26
CA2859668C (en) 2019-01-15
IL233441A0 (en) 2014-08-31
EP2797927A4 (en) 2015-07-08
USRE47451E1 (en) 2019-06-25
IL233441B (en) 2019-05-30
RU2017124993A (ru) 2019-01-30
BR112014015720A8 (pt) 2017-07-04
PH12014501504A1 (en) 2014-10-08
HK1200833A1 (en) 2015-08-14
PE20141404A1 (es) 2014-10-28
CA2859668A1 (en) 2013-07-04
MY170988A (en) 2019-09-23
ES2751608T3 (es) 2020-04-01
RS59420B1 (sr) 2019-11-29
EP3617213A1 (en) 2020-03-04
RU2017124993A3 (es) 2019-01-30
BR112014015720B1 (pt) 2020-03-17
SG11201402765TA (en) 2014-06-27
BR112014015720A2 (pt) 2017-06-13
EP2797927A1 (en) 2014-11-05
AU2012363558B2 (en) 2015-11-19
MX363659B (es) 2019-03-28
TWI462927B (zh) 2014-12-01
CO7010840A2 (es) 2014-07-31
NZ628013A (en) 2016-07-29
PT2797927T (pt) 2019-10-30
CN104039798B (zh) 2016-08-24
KR20130079256A (ko) 2013-07-10
BR122019019582B1 (pt) 2021-07-13
MX2019003468A (es) 2019-06-06
MX2014007230A (es) 2015-05-15
JP2015503553A (ja) 2015-02-02
DK2797927T3 (da) 2019-10-28
WO2013100632A1 (en) 2013-07-04
RU2014131390A (ru) 2016-02-20
HUE045957T2 (hu) 2020-01-28
EP2797927B1 (en) 2019-09-25
RU2625799C2 (ru) 2017-07-19
HRP20191840T8 (hr) 2020-02-07
AU2012363558C1 (en) 2019-08-29
US9156852B2 (en) 2015-10-13
RU2705577C2 (ru) 2019-11-08
HRP20191840T1 (hr) 2019-12-27
SG10201701999QA (en) 2017-04-27
JP5797345B2 (ja) 2015-10-21
IL266285B (en) 2021-12-01
ZA201405583B (en) 2015-10-28
KR101490761B1 (ko) 2015-02-09

Similar Documents

Publication Publication Date Title
AR089489A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
AR103252A1 (es) Compuestos de quinazolina
AR090230A1 (es) Derivados macrociclicos para el tratamiento de enfermedades
DOP2020000191A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina
AR103093A1 (es) Péptidos macrocíclicos que inhiben interacciones proteína / proteína de proteína de la muerte (pd-1 / pd-l1) e inhiben interacción cd80 / pd-l1
AR108875A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
CO6650361A2 (es) Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
AR103828A1 (es) INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR103561A1 (es) Fenilpiridinas herbicidas
PE20151280A1 (es) Compuestos y metodos para la modulacion de quinasas y sus indicaciones
AR092959A1 (es) Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR088760A1 (es) Derivados de pirrolopirimidina y purina
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094174A1 (es) Lactamas fusionadas de arilo y heteroarilo
AR098492A1 (es) Derivados de purina
AR098776A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
CO6650360A2 (es) Derivados de imidazopiridina, su procedimiento de preparació;n y su aplicación en terapéutica
AR092742A1 (es) Piridinonas antifibroticas
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR097436A1 (es) Bis-amidopiridinas
AR099913A1 (es) Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt

Legal Events

Date Code Title Description
FG Grant, registration